Table 1.
Common respiratory virus infections in solid organ transplant recipients
| Virus | Isolation recommendations | Prophylactic interventions | Therapeutic alternatives |
|---|---|---|---|
| Influenza | Contact and droplet | Annual injectable vaccine | M2 inhibitor1 |
| Neuraminidase inhibitor2 | Neuraminidase inhibitor2 | ||
| RSV | Contact | RSV Ig, palivizumab | Aerosolized ribavirin3± IgIV |
| RSV‐active antibodies4 | |||
| PIV | Contact | None | Aerosolized ribavirin |
| hMPV | Contact | None | Aerosolized ribavirin ± IgIV |
| Rhinovirus | Contact | None | None |
| Coronavirus | Standard precautions except for SARS which requires contact, droplet and airborne precautions | None | None |
1Amantadine or rimantadine (for susceptible viruses only).
2Oseltamivir or zanamivir (for susceptible viruses only).
3Oral or IV ribavirin can be used as well, although patients should be monitored for hemolytic anemia; less are available about the efficacy of these formulations in treating RSV than with aerosolized ribavirin.